An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China.
Int J Epidemiol
; 21(3): 564-73, 1992 Jun.
Article
en En
| MEDLINE
| ID: mdl-1386063
ABSTRACT
PIP: Researchers assigned 220 infants born at 5 participating hospitals in Shanghai, China to receive either a 20mcg of an experimental recombinant DNA hepatitis B vaccine (Betagen), a licensed plasma derived hepatitis B vaccine (Lanzhou), 20 mcg of Betagen and hepatitis B immune globulin (HBIG), or 10mcg of Betagen and HBIG to determine the efficacy of Betagen in infants born to mothers with hepatitis B surface antigen (HBsAg) positive. Since China is a hyperendemic hepatitis B carrier area (in Shanghai, for example, prevalence rate is 57%), China hopes to reduce the carrier state via a low cost, safe, immunogenic, and efficacious recombinant vaccine. 20mcg of Betagen resulted in 82.6% efficacy which was significantly higher than that of Lanzhou (51%). The efficacy increased when HBIG was administered with the 20mcg of Betagen (92%). None of the infants born HBsAg negative and/or born to hepatitis B e antigen (HBeAg) mothers later became carriers. Further the HBsAg positive fell from 60-2-% in 9 months whereas these corresponding figures for those who received only Lanzhou were 62.5% and 50%. Even though the percentage of infants with protective levels of antiHBs stood much higher in those who received only Betagen than for those who received Lanzhou in all the months of follow up, except the 1st, their geometric mean titre of antiHBs was not statistically significant. Since Betagen prompted a quick antibody response which probably helped decrease HBsAg in the serum of those infants already positive for HBsAg at birth, it had an advantage over Lanzhou. In conclusion, Betagen given alone proved to be very efficacious in preventing hepatitis B in infants born to carriers of HBsAg. Further it was effective in reducing carriage of HBsAg in infants born HBsAg positive and/or born to HBeAg positive mothers.
Palabras clave
Age Factors; Antibodies; Antigen-antibody Reactions; Asia; Biology; China; Clinical Research; Clinical Trials; Control Groups; Demographic Factors; Developing Countries; Diseases; Double-blind Studies; Eastern Asia; Hepatitis; Immunity; Immunologic Factors; Infant; Methodological Studies; Physiology; Population; Population Characteristics; Research Methodology; Studies; Vaccines; Viral Diseases; Youth
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra Hepatitis Viral
/
Vacunas Sintéticas
/
Portador Sano
/
Hepatitis B
/
Antígenos de Superficie de la Hepatitis B
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Newborn
País/Región como asunto:
Asia
Idioma:
En
Revista:
Int J Epidemiol
Año:
1992
Tipo del documento:
Article
País de afiliación:
Canadá